Novo Nordisk said Sunday that participants who reached a 5% weight-loss threshold by week eight on investigational CagriSema averaged 25.4% weight loss at week 68, in a post hoc analysis.
The company reported that 67.8% of CagriSema-treated participants met the early-response threshold. Its table lists 1,367 early responders and 649 delayed responders, who had lost less than 5% by week eight. By week 68, at least 20% weight loss had been recorded for 73.3% of the early group and 37.2% of the delayed group. Average weight loss in the delayed group was 17.8%.
The figures reflect observed results while participants were still taking the treatment. Novo described the analysis as hypothesis-generating. The two response groups total 2,016 participants; the published REDEFINE 1 trial paper reports that 2,108 participants were assigned to CagriSema. Novo’s announcement did not account for the difference.
In the original 68-week trial, the estimated average weight reduction for the full CagriSema group was 20.4%, compared with 3% for placebo, under a treatment-policy analysis. That trial-wide estimate and the new response-group results use different analyses and participant groupings.
“In clinical practice, it can be hard to know early on how an individual patient will respond to treatment,” said W. Timothy Garvey, an author of the analysis at the University of Alabama at Birmingham.
CagriSema combines cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist. Novo says the treatment is investigational and is not approved in the United States or elsewhere. Novo says it expects a U.S. regulatory decision on CagriSema for weight management in the fourth quarter of 2026. EconoTimes previously covered a separate analysis of women in REDEFINE 1.
Novo’s announcement was timestamped 8 a.m. ET Sunday. Its conference schedule lists the early-response poster for 2:30 to 3:30 p.m. ET that day at ObesityWeek.
